Skip to main content
Petri Dish

Recent Milestones

  • 101 College Street opened in 2024, adding major new laboratory and commercial research space and a permanent home for BioLabs New Haven.

  • Arvinas and Biohaven continue to operate from New Haven headquarters. (Arvinas)

  • Halda Therapeutics was acquired by Johnson & Johnson for approximately $3.05 billion in 2025. (JNJ.com)

  • Yale School of Medicine researchers received approximately $581 million in NIH awards in FY2025, underscoring the scale of biomedical research taking place in the city. (Yale School of Medicine)

  • Continued development of New Haven’s Quantum and Life Science Innovation Cluster is expanding the city’s capacity for research, company growth, workforce development, and private investment.

    Updated August 2026

Resources

BioCT: 203 470 2720

Connecticut Innovations: 860 563 5851

Life Science

New Haven has developed into one of New England’s strongest life sciences centers, built around the close relationship among Yale University, Yale School of Medicine, Yale New Haven Hospital, biotechnology companies, investors, and specialized research facilities. The concentration of research, clinical care, entrepreneurship, and laboratory space has created an environment where discoveries can move from academic research into new companies, clinical development, and commercial investment.

Yale is the foundation of this ecosystem. In federal fiscal year 2025, Yale School of Medicine researchers received approximately $581 million in NIH funding, placing the school among the nation’s leading recipients of biomedical research support. (Yale School of Medicine) That research supports scientists, laboratory staff, graduate students, equipment, facilities, and vendors throughout New Haven while also generating intellectual property and new commercial opportunities.

Yale Ventures helps move university research into the marketplace through licensing, company formation, accelerator programs, mentoring, and connections to investors and industry. New Haven companies that grew from Yale research include Arvinas and Biohaven, both of which continue to maintain headquarters in the city. Arvinas is based at Science Park and is developing targeted protein degradation therapies, while Biohaven is headquartered downtown and is advancing treatments in areas including immunology, neuroscience, obesity, and oncology. (Arvinas)

The value of that commercialization pipeline is also reflected in major acquisitions. Halda Therapeutics, founded on Yale science and based in New Haven, was acquired by Johnson & Johnson for approximately $3.05 billion in 2025, demonstrating the ability of locally developed research to attract substantial outside investment. (JNJ.com)

New Haven has also made significant investments in the physical infrastructure needed to grow life science companies. 101 College Street, completed in 2024, added approximately 500,000 square feet of laboratory and office space in the medical district and includes BioLabs New Haven, a shared laboratory environment designed to help early-stage companies begin and grow without immediately building their own facilities. (BioLabs) The location places startups within walking distance of Yale School of Medicine, Yale New Haven Hospital, downtown, and Union Station.

The next phase of growth is extending beyond individual buildings. New Haven’s Quantum and Life Science Innovation Cluster is intended to connect research institutions, commercial laboratory development, workforce programs, public infrastructure, and private investment in a concentrated area linking downtown, the medical district, and Union Station. That strategy is designed to make it easier for companies to start in New Haven, grow locally, recruit talent, and remain in the city as they mature.

New Haven’s advantage is not simply the number of biotechnology companies located here. It is the ability to bring together research funding, clinical expertise, entrepreneurial support, laboratory space, investment capital, and a skilled workforce within a compact urban setting. That combination continues to attract companies and investment while creating opportunities for both highly specialized researchers and technical workers entering the industry through local education and workforce programs.

Updated August 2026